ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: McIntyre To Replace Frei As Group Chairman Abeloff, Murphy Nominated For ASCO Presidency

January 26, 1990

HHS Proposes Six New DRGs for Leukemia, Lymphoma

July 4, 1986

NCAB Subcommittee Likes Organ Site Program, Except Smoking-Health

April 30, 1976

Peers Puzzled By Herberman’s Stance On Cell Phones While Believers Rally.

August 1, 2008

In Brief: Cancer Control To Push Environmental Research Occupational Hazards; Bailer to Journal Post

May 24, 1974

NCI Gets Concept Approval for New Communications Network

May 27, 1988